BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Neokosmidis G, Tziomalos K. Role of cenicriviroc in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(48): 5415-5417 [PMID: 30622370 DOI: 10.3748/wjg.v24.i48.5415]
URL: https://www.wjgnet.com/1007-9327/full/v24/i48/5415.htm
Number Citing Articles
Michael Doulberis, Kasiani Papadimitriou, Apostolis Papaefthymiou, Jannis Kountouras, Stergios A. Polyzos. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitisExploration of Medicine 2020; 1(4): 170 doi: 10.37349/emed.2020.00012
Zhiyu Wu. Non-alcoholic Fatty Liver Disease: Pathology, Disease Models and TherapiesHighlights in Science, Engineering and Technology 2023; 36: 347 doi: 10.54097/hset.v36i.5702
Laura Draijer, Marc Benninga, Bart Koot. Pediatric NAFLD: an overview and recent developments in diagnostics and treatmentExpert Review of Gastroenterology & Hepatology 2019; 13(5): 447 doi: 10.1080/17474124.2019.1595589
Upasna Madan, Bhawna Verma, Amit Awasthi. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cellsEuropean Journal of Immunology 2024;  doi: 10.1002/eji.202350847